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ABSTRACT
Recent studies employing genome-wide
approaches have provided an unprecedented view
of the scope of L1 activities on structural variations
in the human genome, and further reinforced the
role of L1s as one of the major driving forces
behind human genome evolution. The rapid identifi-
cation of novel L1 elements by these high-
throughput approaches demands improved L1
functional assays. However, the existing assays
use antibiotic selection markers or fluorescent
proteins as reporters; neither is amenable to mini-
aturization. To increase assay sensitivity and
throughput, we have developed a third generation
assay by using dual-luciferase reporters, in which
firefly luciferase is used as the retrotransposition
indicator and Renilla luciferase is encoded on the
same or separate plasmid for normalization. This
novel assay is highly sensitive and has a broad
dynamic range. Quantitative data with high
signal-to-noise ratios can be obtained from 24- up
to 96-well plates in 2–4 days after transfection.
Using the dual-luciferase assays, we have
characterized profiles of retrotransposition by
various human and mouse L1 elements, and
detailed the kinetics of L1 retrotransposition in
cultured cells. Its high-throughput and short assay
timeframe make it well suited for routine tests as
well as large-scale screening efforts.
INTRODUCTION
The preponderance of long interspersed elements type 1
(LINE-1s or L1s) in the human genome was eloquently
revealed by the human genome sequencing project: as the
most abundant autonomous transposable element in the
human genome, they account for  17% of the human
genome mass (1). L1s are arguably one of the major
driving forces behind human genome evolution (2,3).
They shape the genomic architecture through active trans-
position and ectopic recombination between existing
non-allelic homologous elements. In addition to
self-propagation, L1s can mobilize other transcribed
DNA sequences (4,5). A prominent example is Alu
elements, which have outnumbered L1s and account for
 11% of the human genome mass (6). A hominid-speciﬁc
transposon family, SVA elements, is also believed to be
trans-mobilized by the L1 machinery (7,8). L1-mediated
insertional and post-insertional mutagenesis are also
responsible for a wide spectrum of sporadic human
diseases (9,10). A previous survey of full-length L1s
from the reference human genome indicates that there
are 80–100 retrotransposition-competent L1s in an
average human individual, and that a few highly active
(or hot) L1s account for the bulk of retrotransposition
activities in the human population (11). Using
genome-wide approaches, such as paired-end sequencing
of fosmid libraries, microarray (TIP-chip) and deep
sequencing (L1-Seq), recent studies provide an unprece-
dented view of the scope and impact of L1 activities on
structural variations in the human genome (12–15). For
example, a genome-wide study of six individuals identiﬁed
69 dimorphic full-length L1 elements that are absent from
the reference human genome, and the majority of these
L1s were categorized as hot L1s using a retrotransposition
assay (12). Hundreds of novel L1 insertions were
recovered from individual genomes in three independent
genome-wide transposon mapping studies (13–15);
accordingly, the frequency of L1 retrotransposition in
the human germ line has been revised upward to one in-
sertion in every 108 or 140 live births (13,14). One study
also provides strong evidence that L1 can act as a potent
endogenous mutagen in somatic tissues because abundant
de novo L1 insertions were documented in human lung
cancer genomes (15). The rapid identiﬁcation of novel
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sitates the development of improved L1 functional assays.
Cell-based L1 functional assays are essential tools for
studying L1 biology (Table 1). Two types of L1 retrotran-
sposition assays are currently available. The ﬁrst type
employs antibiotic selectable marker genes, such as the
neomycin phosphotransferase gene (neo), and the assay
readout is colony formation (16). Since its inception, the
neo-based assay has been used in all aspects of L1 studies,
leading to the identiﬁcation of essential L1 sequences,
other active L1s, and a wide range of effects that L1
retrotransposition exerts on mammalian genomes (17).
However, this assay typically takes 2–4 weeks to
complete, is labor-intensive and has very low throughput
(16,18). The second type of L1 assay is based on the
enhanced green ﬂuorescence protein (EGFP) (19). It has
a shorter assay timeframe, and usually can be ﬁnished in
7 days. However, the EGFP-based assay has a relatively
narrow dynamic range and lacks sensitivity in higher
density multi-well plates. In order to increase assay sensi-
tivity and throughput, we have now developed a
third-generation assay for L1 retrotransposition using a
dual-luciferase assay scheme: the ﬁreﬂy luciferase (Fluc)
gene is used as the reporter for L1 retrotransposition
and the Renilla luciferase (Rluc) gene for transfection
normalization. Quantitative data can be obtained from
24- to 96-well plates in 2–4 days after transfection by
using common luminometry equipment. This novel assay
is highly sensitive and has a wide dynamic range. Using
this assay, we have characterized retrotransposition by
various human and mouse L1 elements, including the
kinetics of L1 retrotransposition.
MATERIALS AND METHODS
Plasmids
Intron-disrupted Fluc expression cassettes were derived
from pGL4.13 (Promega), which contains a simian virus
40 (SV40) early enhancer/promoter, an optimized Fluc
reporter gene and an SV40 late poly(A) signal. A 900-bp
fragment of the human g-globin intron [or a 133-bp
fragment of the synthetic intron from pCI (Promega)]
was introduced in its antisense orientation into pGL4.13
at nucleotide position 514 of the Fluc reporter gene
through PCR-mediated site-directed mutagenesis,
generating pWA292 (or pWA293). The SV40 late
poly(A) signal in pWA292 (or pWA293) was removed
by FseI(blunted)/BamHI digestion, and replaced by a
BstEII(blunted)/BglII digested herpes simplex virus
thymidine kinase (HSV-TK) poly(A) signal, resulting in
pWA304 (or pWA303). The intron-disrupted Fluc
cassette from pWA304 (or pWA303) was released as a
BglII/EcoRV fragment, which was ligated either to a
PmlI/BamHI digested CMVCAG-ORFeus plasmid to
derive pWA346 (or pWA345), or to a NotI/BstZ17I
fragment of 50-UTR-L1RP from pJCC5-RPS (19) and a
NotI/BamHI fragment from a CMV-less version of
pCEP-Puro (20) to derive pWA355 (or pWA354). The
functional L1RP in pWA355 (or pWA354) was replaced
by the corresponding NotI/BamHI fragment of L1RP/
JM111 from pBS-L1RP(JM111)-EGFP (19) to derive
pWA366 (or pWA356). pWA357 is an L1RP vector with
both CMV and 50-UTR promoters; it was constructed by
ligating a NotI/MluI fragment of 50-UTR-L1RP-Fluc from
pWA355 to NotI/MluI linearized pCEP-Puro backbone.
pWA358 is an L1RP vector with CMV promoter only; it
was constructed by three-way ligation of PvuII/BamHI
and BamHI/MluI fragments from pWA355 and a
NgoMIV(blunted)/MluI fragment of pCEP-Puro.
pWA359 is an L1RP vector with both CMV and CAG
promoters; it was constructed by three-way ligation of
PvuII/BamHI and BamHI/MluI fragments from
pWA355 and an AscI(blunted)/MluI fragment of
pWA346. pWA367 is an L1RP vector with CAG
promoter only; it was constructed by transferring
CAG-L1RP in pWA359 as a NotI/BamHI fragment to
NotI/BamHI linearized pWA355.
Intron-disrupted Rluc expression cassettes were derived
from pGL4.73 (Promega) that contains an SV40 early
enhancer/promoter, an optimized Rluc reporter gene and
an SV40 late poly(A) signal. A 900-bp fragment of the
human g-globin intron (or a 133-bp fragment of the syn-
thetic intron from pCI) was introduced in its antisense
orientation into pGL4.73 at nucleotide position 206 of
the Rluc reporter gene through PCR-mediated site-
directed mutagenesis, generating pWA296 (or pWA297).
The SV40 late poly(A) signal in pWA296 (or pWA297)
was removed by FseI(blunted)/BamHI digestion, and
replaced by a BstEII(blunted)/BglII digested HSV TK
poly(A) signal, resulting in pWA307 (or pWA306). The
intron-disrupted Rluc cassette from pWA307 (or
pWA306) was released as a SalI(blunted)/BglII fragment
(or a BglII/HincII fragment), and ligated to a
PmlI/BamHI digested CMVCAG-ORFeus plasmid to
derive pWA349 (or pWA348).
pWA003 and pWA196 are two control vectors.
pWA003 contains an EGFP expression cassette on a
pCEP-Puro backbone. It was derived by ligating the
EGFP gene as a NheI/BamHI fragment from pEGFP-
C1 (Clontech) into NheI/BamHI linearized pCEP-Puro.
pWA196 contains a 50-UTR-L1RP element tagged by an
EGFP retrotransposition indicator. It was created by
ligating a NotI/BstZ17I fragment of 50-UTR-L1RP from
pJCC5-RPS and a SalI(blunted)/BamHI fragment of
pBSKS-EGFP-INT (19) into NotI/BamHI linearized
CMV-less version of pCEP-Puro.
pYX013, pYX014, pYX015, pYX016 and pYX017 are
plasmids for single-vector assays, and they all contain an
intact Rluc expression cassette on the vector backbone for
Table 1. Characteristics of different L1 reporter assays
Reporter Protocol Timeframe
(days)
a
Special
instrument
Thoughput Reference
neo Standard 32–38 No  6 well (16)
neo Transient 15 No  6 well (18)
EGFP Standard 7 Flow cytometer 6 well (19)
Fluc Standard 2–4 Luminometer 24, 96 well This study
aDays post transfection.
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expression cassette was derived from pGL4.73 in two
subcloning steps. The SV40 late poly(A) signal in
pGL4.73 was ﬁrst removed by FseI(blunted)/BamHI
digestion, and replaced by an HSV TK poly(A) signal
with BstEII(blunted)/BglII ends, resulting in pWA305.
The SV40 early enhancer/promoter in pWA305 was then
removed by FspI/HindIII digestion, and replaced by an
HSV TK promoter as an FspI/HindIII fragment, resulting
in pTT010. pWA003 was partially digested by EcoRI, and
the EcoRI ends were blunted by Klenow and subsequently
religated to create pYX011, which lacks the EcoRI site at
nucleotide position 7965. The Rluc cassette was released
from pTT010 as an FspI/PciI fragment and ligated into
EcoRI(blunted)/PciI digested pYX011 to make pYX013.
The 50-UTR-L1RP-Fluc element was released from
pWA355 as a SacII/PvuI fragment, and ligated to two
pYX013 fragments (SacII/MluI and MluI/PvuI) to
create pYX014. The 50-UTR-L1RP/JM111-Fluc element
was released from pWA366 as an SacII/PvuI fragment,
and ligated to two pYX013 fragments (SacII/MluI and
MluI/PvuI) to create pYX015. The CAG-L1RP-Fluc
element was released from pWA367 as a NotI/SwaI
fragment, and ligated to NotI/SwaI linearized pYX014
to create pYX017. The CAG-ORFeus-Fluc element was
released from pWA346 as a NotI/SwaI fragment, and
ligated to NotI/SwaI linearized pYX014 to create
pYX016.
Cell culture
HeLa cells were grown at 37 C in a humidiﬁed 5% CO2
incubator in Dulbecco’s Modiﬁed Eagle’s Medium
(DMEM) supplemented with 10% fetal bovine serum
and 2mM stable dipeptide of L-alanyl-L-glutamine. Cells
were passaged every three days by using 0.25% porcine
trypsin. All medium components for HeLa cell culture
were purchased from Hyclone.
L1 retrotransposition assay
HeLa cells were seeded in 24-well plates at a density of
7 10
4 cells/well and grown up to 60–70% conﬂuence.
Endotoxin-free plasmid DNA was prepared with
anion-exchange resin columns (Qiagen) and diluted in
sterile 10mM Tris–HCl buffer. Cells were transfected
with Lipofectamine 2000 reagent (Invitrogen) following
the manufacturer’s protocol. Each well received 200ng
plasmid DNA in the single-vector assay, 0.6ml
Lipofectamine 2000 reagent and 100ml GlutaMAX-I-
supplemented Opti-MEM I reduced-serum medium
(Invitrogen). In the two-vector assay, a 20:1 ratio of L1
plasmid (200ng) and the Rluc control plasmid
pGL4.73 (10ng) was used. Puromycin (Sigma-Aldrich)
was added in complete medium at a ﬁnal concentration
of 2.5mg/ml at 24h post-transfection. Cells were harvested
4 days post-transfection for luciferase activity analysis
unless otherwise indicated. To perform single-vector
assays in 96-well plates, HeLa cells were seeded at
a density of 1 10
4 cells/well and grown up to 80–85%
conﬂuence. One-hundred-nanogram plasmid DNA,
0.3ml Lipofectamine 2000 reagent and 50ml
GlutaMAX-I-supplemented Opti-MEM I reduced-serum
medium were used per well.
Nucleoside reverse transcriptase inhibitors dosing and
kinetics assays
HeLa cells were seeded in 24-well plate and transfected
with L1 plasmids as described above. All nucleoside
reverse transcriptase inhibitors (NRTIs) were acquired
from Sigma-Aldrich, including 20-30-didehydro-20-30-
dideoxythymidine (d4T), 20-30-dideoxy-30-thiacytidine
(3TC) and 2030-dideoxyinosine (ddI). To determine effect-
ive concentrations, NRTIs were added to the culture
medium at 2h before transfection, and were replenished
every 24h onwards until the endpoint of an experiment.
To determine L1 retrotransposition kinetics, cells in
parallel wells were treated with NRTIs at 2h before trans-
fection, or 16, 24, 28, 32, 40 and 48h post-transfection,
respectively. Untreated cells were used as controls for full
activity. Puromycin was supplemented during each
medium exchange starting from 24h post-transfection.
Cells were harvested 4 days post-transfection for
luminescence analysis.
Dual-luciferase luminescence measurement
Luminescence was measured using the Dual-Luciferase
Reporter Assay System (Promega) following the manufac-
ture’s instructions. For assays in 24-well plates, 100ml
Passive Lysis Buffer was used to lyse cells in each well;
for assays in 96-well plates, 25ml was added per well. For
all assays, 20ml lysate was transferred to a solid white
96-well plate, mixed with 100ml Luciferase Assay
Reagent II and Fluc activity was read on a GloMax-
Multi Detection System (Promega). Rluc activity was sub-
sequently read after mixing 100ml Stop & Glo Reagent
into the cell lysate containing Luciferase Assay Reagent II.
Data normalization and statistical analysis
To facilitate comparison of L1 activities from different
elements, we calculated a normalized luminescence ratio
(NLR) for each vector (see ‘Results’ section). We routinely
used the retrotransposition-defective L1RP/JM111 as the
reference Fluc vector. In all our tests, Fluc signals were
indistinguishable between L1RP/JM111 and EGFP-
expressing vectors carrying the same vector backbone.
However, Rluc signals were typically 1.5- to 2.0-fold
lower for EGFP-expressing vectors (i.e. pWA003 and
pYX013) than those for L1RP/JM111 in the same assay
(data not shown). Such differences in Rluc signals can
explain why EGFP-expressing control vectors had NLR
values slightly higher than expected (in the range of
1.4–2.2 when L1RP/JM111 was used as the reference
vector). The relative reduction of Rluc signals in cells
transfected with EGFP-expressing vectors is likely
caused by promoter interference, in which a strong
promoter interferes with the test promoter by competing
for general or speciﬁc transcription factors. We used a
constant amount of DNA for different transfections, but
1.7- to 2-fold more DNA was used for the control
plasmids due to their smaller sizes. In fact, Rluc signals
from L1RP/JM111 were highly similar to those from
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retrotransposition-defective L1 is best suited to serve as
the reference Fluc vector. However, this does not exclude
the use of non-L1 vectors, such as pWA003 or pYX013, as
reference Fluc vectors as long as the same vector is used as
the reference for all assay conditions. To compare
retrotransposition rates between different conditions, we
used two-tailed Student’s t-test.
Genomic DNA PCR and quantitative PCR
To conﬁrm intron removal from de novo L1 insertions,
HeLa cells transfected with pYX013, pYX014 or
pYX015 were harvested at 48h post-transfection.
Genomic DNA was extracted with a DNeasy Tissue Kit
(Qiagen). pGL4.13 plasmid DNA was used as an intron-
control; pWA292 was used as an intron+ control. The
following primers speciﬁc to the Fluc coding sequence
were used with ExTaq polymerase (Takara): Fluc-P1
50-CAACGTGCAAAAGAAGCTACC-30 and Fluc-P2
50-ATGACTGAATCGGACACAAGC-30. The PCR
cycling parameters consist of an initial denaturation at
94 C for 2min, 30 cycles of denaturing at 94 C for 15s,
annealing at 60 C for 30s and extending at 72 C for 30s,
and a ﬁnal extension step at 72 C for 7min. PCR product
was resolved on a 1% agarose gel containing 0.5mg/ml
ethidium bromide, and documented with a Gel Doc XR
system (Bio-Rad). To determine the copy number of de
novo L1 insertions, we performed quantitative PCR
(qPCR) according to a previously established protocol
(21). For each genomic DNA sample, L1 insertions were
ampliﬁed in triplicate with primers and an exon-exon
junction probe speciﬁc to the Fluc gene. Human
GAPDH was ampliﬁed in parallel wells as an endogenous
control for normalization. The following primers and
probes were used: GAPDH forward 50-CCCACTCCTC
CACCTTTGAC-30, GAPDH reverse 50-TGTTGCTGTA
GCCAAATTCGTT-30, GAPDH probe 50-AAGCTCATT
TCCTGGTATGA-30; Fluc forward 50-GCAAAAGAAG
CTACCGATCATACA-30, Fluc reverse 50-GAAGCTCT
CGGGCACGAA-30, Fluc exon-exon junction probe 50-C
TTCCCACCTGCCACC-30. qPCR data were analyzed by
the comparative CT method, and normalized to signals
from cells transfected with CAG-ORFeus and harvested
at 48h post-transfection. Each data point represents
average±SE from four separate transfections.
RESULTS
A two-vector dual-luciferase assay for L1
retrotransposition
We implemented a dual-luciferase scheme for assaying L1
retrotransposition. The Fluc gene was used to report L1
activity (Figure 1A). As in previous L1 reporter assays, the
coding sequence of the Fluc reporter gene was interrupted
by an antisense intron. As expected, no Fluc signal was
detected above background when a stand-alone
intron-disrupted Fluc reporter cassette was transfected
into HeLa cells (data not shown). The Fluc cassette was
ﬁrst tested as a reporter for L1RP.L 1 RP is the causative
full-length L1 insertion isolated from a patient with
retinitis pigmentosa (22). It remains one of the most
active endogenous L1 elements identiﬁed thus far and
has been featured in a wide range of L1 studies. The
Fluc cassette was inserted in the 30-untranslated region
(30-UTR) of L1RP in the antisense orientation relative to
L1 expression. Such a sequence arrangement ensures that
Fluc signals arise in transfected cells only after the donor
L1 has undergone one round of retrotransposition
Figure 1. A two-vector dual-luciferase assay for L1 retrotransposition.
(A) Diagrams of a Rluc control vector (3.9kb) and an L1 vector tagged
by an intron-disrupted Fluc reporter (18.3kb for pWA355). L1 is ex-
pressed from a pCEP4-based episomal plasmid, and marked by a
Fluc gene interrupted by an antisense intron (also known as a
retrotransposition reporter). The Fluc cassette has its own
promoter (P2) and polyadenylation signal, and is expressed from the
antisense strand relative to the L1 promoter (P1). (B) The rationale of
L1 retrotransposition assay. The level of L1 retrotransposition is
detected as Fluc activity. No Fluc signal is expected in transfected
cells unless the donor L1 has undergone one round of retrotran-
sposition (i.e. transcription, splicing, reverse transcription and integra-
tion into the genome). Adapted from Moran et al. (16). (C) A typical
workﬂow in 24-well plates. (D) Detection of L1 retrotransposition
with a two-vector dual-luciferase assay. Either L1RP or L1RP/JM111
(a mutated L1RP carrying two missense mutations in ORF1) was
used as the donor element. Two different introns were used to construct
the Fluc reporter cassette. L1 activity is expressed as NLRs relative to
the background signal from pWA366. Error bars represent mean±SE
(N=4).
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integration into the genome) (Figure 1B). The Rluc gene
was used to normalize transfection efﬁciency by
cotransfection (Figure 1A). A standard assay was
performed in 24-well plates, and could be completed in
4 days post-transfection (Figure 1C). Brieﬂy, HeLa cells
were cotransfected with a Fluc-tagged L1 vector and a
Rluc control vector. Transfected cells were selected with
puromycin at 24 h post-transfection, and lysed for
luminescence analysis at 4 days post-transfection.
Luminescence was measured in a 96-well plate, and
could be completed within 30min starting from cell lysis.
We ﬁrst assessed the background luminescence for both
Fluc and Rluc activities by using several control vectors,
including an L1RP tagged with an EGFP retrotran-
sposition indicator (pWA196) and an EGFP expression
vector in the same plasmid backbone (pWA003); both
showed background level of luminescence that was indis-
tinguishable from mock transfected cells (Figure 1D).
Such background luminescence was consistent from
experiment to experiment, and ranged from 100 to 300
relative light units (RLUs). Cells cotransfected with the
Rluc control vector yielded Rluc signals >1000-fold
above the background. Fluc signals from cells transfected
by L1RP vectors (pWA355) were >100-fold above the
background (Figure 1D). To conﬁrm that the observed
Fluc signals were originated from L1 retrotransposition,
we tagged L1RP/JM111, which carried missense mutations
in the ORF1 coding sequence. These mutations have pre-
viously been shown to completely abolish L1 retrotran-
sposition (16). As expected, Fluc readings from L1RP/
JM111 vectors (such as pWA366) were indistinguishable
from background luminescence (Figure 1D). To facilitate
comparison of L1 activities from different elements, we
calculated a NLR for each vector. L1RP/JM111 was
used as the reference Fluc vector (the choice of reference
vector is discussed in Materials and methods section). For
example, NLRpWA355=(Fluc pWA355/Rluc pWA355) / (Fluc
pWA366/Rluc pWA366). In a representative experiment, an
NLR value of 363 was obtained from the 50-UTR-L1RP
element (Figure 1D), indicating that the 50-UTR-L1RP
element retrotransposed at a level that was 363-fold
higher than that observed with a retrotransposition-
defective L1.
Choice of introns for L1 reporter
We tested two different introns for their suitability to
disrupt the luciferase reporter gene. The ﬁrst intron is
from the human g-globin gene, which has been previously
used in neo- and EGFP-based reporters (16,19). The
second is a small synthetic intron from plasmid pCI,
which was chosen for its smaller size. Their effects on
L1 activity were tested by using 50-UTR-L1RP as the
donor element (Figure 1D). A 3.5-fold higher Fluc
signal was observed when the g-globin intron was used
in the Fluc reporter than when the pCI intron was used,
presumably because the g-globin intron had a higher
splicing efﬁciency (Figure 1D, comparing pWA355 to
pWA354). These two introns were also tested as part of
the Fluc reporter cassette when a hyperactive synthetic
mouse L1, ORFeus (23,24), was used as the donor
element (Figure 2A). The hyperactive nature of ORFeus
was indeed conﬁrmed by the new luciferase-based assay:
ORFeus generated Fluc signals at more than 8000-fold
above the background (Figure 2A). Interestingly, the
choice of intron did not signiﬁcantly affect the overall
L1 activity when ORFeus was used as the donor: a Fluc
cassette containing the pCI intron yielded a 12% higher
signal than the g-globin-intron-containing Fluc cassette
(Figure 2A). Thus the intron efﬁciency appears to be
inﬂuenced by long range sequence context. This may be
due to the extent to which cryptic splice sites within each
element contribute to aberrant splice variants that reduce
overall retrotransposition efﬁciency. We decided to use the
g-globin intron for later experiments because it tends to
generate higher Fluc signals when the overall L1 activity is
in the lower range, as is the case when 50-UTR-L1RP was
used as the donor (Figure 1D). This conclusion was also
supported by the following experiments when ORFeus was
used as the donor element and Rluc was used as the
retrotransposition reporter (Figure 2B, discussed below).
Choice of luciferase genes as L1 reporter
In dual-luciferase applications, Fluc is preferred over Rluc
as the ‘experimental’ reporter, while Rluc is reserved as the
‘control’ reporter for signal normalization, because the
dynamic range of Fluc is one order of magnitude higher
than that of Rluc. However, a unique feature of L1
retrotransposition assays is that signals from the experi-
mental reporter can only be generated from de novo L1
insertions that contain an intact (i.e. full length) experi-
mental reporter cassette. Since the majority of L1 inser-
tions are 50 truncated (25,26), the length of a reporter gene
could potentially be a critical factor in determining the
overall L1 activity that can be observed. As the Rluc
gene (936bp) is 1.8-fold shorter than the Fluc gene
(1653bp), we decided to test whether Rluc was more efﬁ-
cient than Fluc as an L1 reporter for the hyperactive
ORFeus element (Figure 2B). As compared to
Figure 2. Evaluation of different luciferase genes and introns for L1
reporters. (A) Use of Fluc as the L1 reporter and Rluc as the
cotransfection control. Either pCI or g-globin intron was used to
disrupt the Fluc reporter cassette. (B) Use of Rluc as the L1 reporter
and Fluc as the cotransfection control. Either pCI or g-globin intron
was used to disrupt the Rluc reporter cassette. In both (A and B),
CMV-CAG-ORFeus was used as the donor L1. L1 activity is expressed
as NLRs relative to the background signal from pWA003. Error bars
represent mean±SE (N=4).
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mental signal was observed for Rluc-based reporters: a
45-fold decrease when the pCI intron was used to
disrupt the reporter gene (comparing pWA345 and
pWA348) and a 28-fold decrease when the g-globin
intron was used (comparing pWA346 and pWA349)
(Figure 2). Thus, we conﬁrmed that Fluc was superior to
Rluc when used to report L1 activity, despite its longer
coding sequence.
The utility of two-vector dual-luciferase assay for
detecting L1 activities with different promoters
To demonstrate the sensitivity of the newly established
two-vector dual-luciferase assay, we tested whether it
could distinguish retrotransposition levels of several L1
retrotransposition vectors with different promoters or
tandem combinations of promoters. We compared L1RP
elements under the regulation of its native promoter
(50-UTR), and several heterologous promoters, including
CMV, CAG and tandem promoters (Figure 3). Among all
promoters tested, the lowest L1 activity was observed
from the CMV promoter (NLR=69), and the highest
activity was from the CAG promoter (NLR=1404), rep-
resenting a 20-fold activity range. Other promoter(s) dis-
played intermediate L1 activities at the following order:
CAG>CMV+CAG>CMV+50-UTR>50-UTR>CMV
(Figure 3).
A single-vector dual-luciferase assay for L1
retrotransposition
Thus far, we have demonstrated dual-luciferase assays for
L1 retrotransposition by using two separate plasmids: an
L1 plasmid tagged with a Fluc reporter, and a control
plasmid encoding Rluc. To test any L1 plasmid in the
two-vector assay, cotransfection with the control
plasmid at a consistent molar ratio of 20:1 (L1-Fluc
vector versus the Rluc control) is required. To further
simplify experimental protocol and minimize experimental
variation, we tested a single-vector dual-luciferase strategy
(Figure 4). In the single-vector conﬁguration, a Rluc ex-
pression cassette was incorporated into the backbone of
the L1 assay vector (Figure 4A). We modiﬁed the Rluc
cassette by using a weaker HSV-TK promoter (the control
Rluc vector pGL4.73 used in the two-vector assay carries
an SV40 promoter). The promoter exchange yielded
optimal Rluc signals for the one-vector assay as the
Rluc cassette was present at a molar ratio of 1:1 relative
to the L1 element. In addition, sequence elements respon-
sible for episomal maintenance of pCEP-Puro derived
plasmids were removed from the single assay vector.
These sequences include the EBNA-1 gene and
Epstein-Barr virus replication origin oriP, which were
dispensable for neo-based L1 assays (20). Consequently,
the overall size of the assay vector was reduced by 3.2kb
(comparing Figure 1A to Figure 4A).
We tested the single-vector dual-luciferase scheme by
comparing L1 activities from several different L1
elements (Figure 4B). The 50-UTR-L1RP element
(pYX014) displayed an NLR signal of 383-fold above
background, comparable to the two-vector assay (see
pWA355 in Figure 1D). Substitution of the L1 50-UTR
by a strong CAG promoter increased retrotransposition
2.7-fold (pYX017, NLR=1017). Further substitution of
L1RP by ORFeus resulted in another 45-fold increase
on overall retrotransposition activity (pYX016,
NLR=46067).
The superlative activity from the CAG-ORFeus element
made it possible to measure the dynamic range of our
luciferase-based L1 assays. Serial dilutions of CAG-
ORFeus transfected cells yielded linear signals for both
Fluc and Rluc in the range from 800 to 500000 cells
(Figure 4C). This is equivalent to a minimum of
600-fold dynamic range. The weakest Fluc signals from
this experiment were obtained from 800-cell samples,
and remained signiﬁcantly above the background lumines-
cence ( 53-fold) at an average of 10558 RLUs. To further
conﬁrm that Fluc signals result from L1 retrotran-
sposition, we monitored intron removal by genomic
DNA PCR (Figure 4D). Genomic DNA from transfected
HeLa cells were ampliﬁed by primers ﬂanking the g-globin
intron in the Fluc reporter cassette (Figure 4A). An
intronless band of 250bp was present in cells transfected
with a retrotransposition-competent 50-UTR-L1RP
element (pYX014) but absent in cells transfected with an
L1RP/JM111 element (pYX015), indicating that a func-
tional Fluc gene was reconstituted as the result of
retrotransposition (Figure 4D).
Using reverse transcriptase inhibitors to evaluate the
kinetics of L1 retrotransposition
The kinetics of L1 retrotransposition has been recently
investigated by using a neo-based L1 reporter assay and
timed d4T treatment (27). As an NRTI, d4T inhibits
reverse transcription after being incorporated into the
growing cDNA chain because the phosphorylated d4T
lacks a 30-hydroxyl group. Thus, in such experiments,
the timing of L1 retrotransposition is deﬁned as the time
required for L1 reverse transcriptase to complete reverse
transcription after the donor L1 is transfected into cells.
Note this operational deﬁnition does not cover the
remaining steps of L1 retrotransposition, such as the
second strand synthesis and subsequent integration of a
new copy of L1 into the genome. To evaluate the kinetics
Figure 3. Effect of different promoters on L1 retrotransposition. L1
activity is expressed as NLRs relative to the background signal from
pWA366. Error bars represent mean±SE (N=6).
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assay, we ﬁrst determined effective inhibitory concentra-
tions of several NRTIs in our assay with 50-UTR-L1RP as
the donor element. In such tests, NRTI treatment started
at 2h before transfection and was maintained throughout
the assay (Figure 5A). Consistent with previous reports,
50mM d4T showed potent inhibition of L1 retrotran-
sposition and reduced Fluc signals to background. Two
other NRTIs, 3TC and ddI, were even more potent than
d4T (Supplementary Figure S1A). In addition, no overt
cytotoxicity was witnessed at these testing conditions (not
shown).
We determined retrotransposition kinetics of
50-UTR-L1RP by adding 50mM 3TC at different time
points before or post-transfection (Figure 5A). For each
time point assayed, the drug was replenished daily until
the cells were lysed at 96h post-transfection for lumines-
cence measurement. Relative to the  2h control, a 9-fold
increase of L1 activity was ﬁrst detected at the 28-h time
point (Figure 5B, P=0.14). The level of L1 activity
reached statistical signiﬁcance at the 32-h time point
(15-fold; P<0.05). The overall kinetics of L1 retrotran-
sposition by 50-UTR-L1RP were similar when cells were
treated with d4T (Supplementary Figure S1B). In both
cases, a signiﬁcant fraction of L1 retrotransposition
events had occurred by 48h post-transfection (39% for
3TC treated cells and 28% for d4T), the latest time
point that cells were treated with either NRTI.
We also examined the kinetics of L1 retrotransposition
in cultured cells for CAG-L1RP and CAG-ORFeus
elements (Figure 5B). These two vectors had substantially
higher activities than 50-UTR-L1RP in the absence of
NRTI treatment (Figure 4A); nevertheless, 50mMo f
3TC could effectively reduce L1 signals to below 0.1%
relative to the untreated control (Supplementary
Figure 4. A single-vector dual-luciferase assay for L1 retrotransposition. (A) Diagram of a dual-luciferase assay vector in a single-vector format
(15.1kb for pYX014). (B) Evaluation of L1 vectors with different coding sequences and promoters. L1 activity is expressed as NLRs relative to the
background signal from pYX015. Error bars represent mean±SE (N=4). (C) Assay dynamic range. HeLa cells were transfected with pYX016.
Cells were counted before lysis. Cell lysates were serially diluted by 5-fold and measured for luminescence. Data represent mean±SE (N=3). The
level of background signals is indicated (ranging from 100 to 300 relative lights units). (D) Conﬁrmation of retrotransposition by PCR. HeLa cells
were transfected by each L1 plasmid, and genomic DNA was ampliﬁed by an intron-ﬂanking primer pair (shown as arrows in A). The presence of a
band of 250bp is diagnostic for intron removal; the intron-containing donor DNA is ampliﬁed as a band of 1150 p. NTC, no template control. Fluc
plasmids with or without the intron are used as controls. Molecular weight was indicated by 1kb Plus DNA Ladder (Invitrogen).
Figure 5. Kinetics of L1 retrotransposition. (A) Procedure for NRTI
treatment. L1 assays were performed following the standard assay pro-
cedure except the NRTI treatment: HeLa cells were treated with an
NRTI at  2(i.e. 2h before transfection), 16, 24, 28, 32, 40 or 48h
post-transfection. The duration of drug treatment is indicated by hori-
zontal lines below the time axis. (B) Measurement of kinetics with 3TC.
Cells were transfected with 50-UTR-L1RP (pYX014), CAG-L1RP
(pYX017), CAG-ORFeus (pYX016) or retrotransposition-incompetent
50-UTR-L1RP/JM111 (pYX015). Reverse transcription was inhibited at
each time point by 50mM 3TC. Luminescence was measured at 96h
post-transfection. L1 activity for each condition is ﬁrst calculated as
normalized Fluc/Rluc values, and then expressed as relative activities
by setting Fluc/Rluc values from the  2 h control as 1. Note the 96-h
data points represent cells not treated with 3TC. Error bars represent
mean±SE (N=4). Retrotransposition at each data point was
compared to the  2 h control by two-tailed Student’s t-test
(*P<0.05, **P<0.01, ***P<0.001).
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elements displayed highly similar kinetics as compared
to 50-UTR-L1RP under 3TC treatment (Figure 5B). For
CAG-ORFeus, reproducible signals were detected as
early as at the 24 h time point (14-fold increase relative
to the  2 h control; P< 0.01). Overall, L1 retrotran-
sposition conforms to exponential kinetics that can be
divided into three phases: a lag phase encompassing the
ﬁrst 24h, an exponential phase between 24 and 48h (R
2
ranges from 0.943 to 0.984), and a steady phase after 48h
(Figure 5B).
The time-course of L1 retrotransposition in single-vector
assays
In our standard protocol, the frequency of retrotran-
sposition is determined at 4 days post-transfection. We
consistently obtain robust NLR signals at 4 days
post-transfection in both two-vector and one-vector
assays for all donor L1 vectors tested:  300 for
50-UTR-L1RP,  1000 for CAG-L1RP and  10000 for
CAG-ORFeus. To determine whether it would be
feasible to detect L1 activities at even earlier time points,
we harvested cells at 2, 3 and 4 days post-transfection in a
one-vector assay (Figure 6A). Indeed, using 50-UTR-L1RP
as the donor element, we were able to detect signiﬁcant L1
activities starting at 2 days post-transfection (NLR=15,
P<0.01; Figure 6B). L1 activity increased to 110-fold
above background at 3 days post-transfection and to
242-fold above background at 4 days post-transfection.
Similar time course was observed for the hyperactive
CAG-ORFeus element (Figure 6B). Not surprisingly,
CAG-ORFeus displayed strong retrotransposition signals
at all three time points. At 2 days post-transfection, its
NLR has reached 288-fold above background
(P<0.0001).
We reasoned that the strong signal at 2 days
post-transfection from CAG-ORFeus should permit
further characterization of the time course of L1
retrotransposition within the ﬁrst 48h. Thus, we trans-
fected CAG-ORFeus vector (pYX016) into HeLa cells,
lysed and measured luciferase reporter activities at 3-h
intervals from 12 to 48 h post-transfection. We plotted
raw Fluc signals as RLUs over time (Figure 6C). No sig-
niﬁcant Fluc signals were detected in the ﬁrst 30h; there-
after, Fluc signals increased exponentially (R
2=0.972 for
signals between 30 and 48h). In fact, reproducible signals
were ﬁrst detected at 33 h post-transfection (P<0.01). To
control for well-to-well variations in cell number, we
normalized the raw Fluc signals to the number of cells
in each well (Supplementary Figure S2A). Again, signiﬁ-
cant signals ﬁrst appeared at 33h (P<0.05), and exponen-
tially increased thereafter (R
2=0.979 for normalized
signals between 30 and 48h).
In the previous section on retrotransposition kinetics,
we have shown that a minimum of 24h are required for
CAG-ORFeus activity to be detected at a statistically sig-
niﬁcant level (Figure 5B). In that experiment, L1 reverse
transcription was stopped at 24h post-transfection but the
cells were grown for additional 72h in the presence of
3TC. This delay in luciferase measurement not only gave
Figure 6. The time course of L1 retrotransposition. (A) Procedure for
time course experiments. Cells were harvested at 2, 3 or 4 days
post-transfection, lysed and measured for luminescence. (B) Detection
of 50-UTR- L1RP and CAG-ORFeus activities between 2 and 4 days
post-transfection. L1 activity is expressed as NLRs relative to the back-
ground signal from pYX015. Error bars represent mean±SE (N=4).
(C) Detection of CAG-ORFeus activities before 48h post-transfection.
HeLa cells were transfected with pYX016 at time zero, and lysed for
luminometry analysis at indicated time points. Raw Fluc signals are
plotted as RLUs for each time point. Untransfected HeLa cells were
used as a control for background luminescence (the 0-h time point).
Fluc signals from each time point were compared to time zero by
two-tailed Student’s t-test; statistically signiﬁcant P-values are indicated
over the x-axis (*P<0.05, **P<0.01). Error bars represent mean±SE
(N=4). (D) Quantiﬁcation of de novo L1 insertions by qPCR.
Genomic DNA was extracted from an aliquot of cells described in C,
and the relative number of L1 insertions was determined by a
TaqMan-based qPCR assay. The relative positions of Fluc primers
(arrows) and probe (an open rectangle between the primers) are
illustrated (inset). qPCR signals were normalized by setting signals
from the 48-h time point to 1. The normalized signals from each
time point were then compared to the 12-h time point by two-tailed
Student’s t-test; P-values are indicated over the x-axis (*P<0.05,
**P<0.01, ***P<0.001). Error bars represent mean±SE (N=4).
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the de novo L1 insertions, but might have also ampliﬁed
the total signal output due to cell division. In contrast, the
minimum of 33h determined by the time-course experi-
ment are the time required for DNA uptake, L1 retrotran-
sposition (i.e. from transcription, translation, reverse
transcription to integration), and reporter gene expression
(i.e. transcription and translation of Fluc) (Figure 6C).
Thus, the 9-h lag in the time-course experiment reﬂects
the time that is needed for the reporter gene to be ex-
pressed from L1 insertions.
Reporter genes for L1 retrotransposition are prone to
epigenetic silencing [(28); J. Li, M. Kannan, J. D. Boeke
and D. E. Symer, personal communication]. Thus, our
measurement of L1 kinetics and/or retrotransposition
time course may be confounded by some unknown char-
acteristics in reporter gene expression. To corroborate our
kinetics data, we measured the number of de novo L1
insertions in cells harvested from above time-course
experiment by a previously established qPCR method,
which is totally independent of reporter gene expression.
Overall, we observed an exponential increase of de novo
L1 insertions during the assay timeframe (Figure 6D,
R
2=0.985). Statistically signiﬁcant signals were ﬁrst
detected by qPCR at 21 h post-transfection (normalized
activity=1.7%, P<0.05), and a normalized activity of
9.1% was reached by 33h post-transfection. In addition,
the qPCR data displayed a good correlation with the
retrotransposition data from 33 to 48 h post-transfection
(Supplementary Figure S2B, R
2=0.946).
Miniaturization of single-vector assays into a 96-well
format
Ninety-six-well plates or higher density format have
become the standard platform for assay automation.
With robust signals from 24-well plates, we evaluated
the performance of the new single-vector dual-luciferase
assay in a 96-well format (Figure 7). NLR signals compar-
able to those acquired from 24-well plates were obtained
for all L1 elements tested: 193-fold above background for
50-UTR-L1RP, 1066-fold for CAG-L1RP and 26594-fold
for CAG-ORFeus (Figure 7; R
2=0.996 between 24- and
96-well plates).
DISCUSSION
We have developed novel dual-luciferase reporter assays
for L1 retrotransposition. In contrast to existing neo-o r
EGFP-based assays, the new luciferase-based assays have
several signiﬁcant improvements. First, it has the shortest
assay timeframe. The standard luciferase assay developed
here requires only 4 days from transfection to data collec-
tion (Table 1). Our time-course results indicate that it can
be shortened to 3 days from transfection for the standard
50-UTR-L1RP element and to 2 days from transfection for
the hyperactive CAG-ORFeus element, while maintaining
a signal of >100-fold above background (Figure 6B).
Second, the assay requires minimal hands-on time
beyond transfection. Selection with puromycin is simply
achieved by medium exchange; quantitative data can be
rapidly collected from >96 samples within a half hour.
Third, the assay displays superlative signal-to-noise
ratios. The native 50-UTR-L1RP element consistently
yields NLR signals >100-fold above background. In
contrast, the EGFP-based assay is often compromised
by a high background due to autoﬂuorescence: at 6 days
post-transfection,  2.5% of cells transfected with
50-UTR-L1RP were EGFP-positive, while 0.02–0.26% of
cells were considered positive from control transfections
with the vector backbone (19). Fourth, the assay has a
very broad dynamic range. A minimum 600-fold linear
dynamic range was conﬁrmed by serial dilution experi-
ments. The actual dynamic range may be larger because
L1 activities can be reproducibly detected in the range
from NLR=15 (at 2 days post-transfection for
50-UTR-L1RP; Figure 6B) to over 46000 (at 4 days
post-transfection for CAG-ORFeus; Figure 4A). Lastly,
the luciferase-based retrotransposition assay can be
performed either in a two-vector format or in a single-
vector format. The single-vector assay format offers an
additional advantage because the internal Rluc control is
encoded on the same vector. This eliminates variations
due to imprecise pipetting or quantiﬁcation of absolute
concentrations of different plasmids.
We investigated the kinetics of L1 retrotransposition in
cell culture using three different approaches. We ﬁrst used
NRTIs to measure the timing of L1 retrotransposition,
deﬁned operationally as the time required for L1 reverse
transcriptase to complete reverse transcription after the
donor L1 is transfected into cells. In a previous study, a
neo-based L1 reporter assay was employed and d4T was
used to inhibit L1 reverse transcription at different time
points post-transfection (27). Few G418-resistant colonies
were observed when d4T was added at 32h post-
transfection, and  20% of L1 retrotransposition
(relative to untreated controls) had occurred when d4T
was added at 42 h post-transposition (27). With its unpre-
cedented sensitivity and dynamic range, our luciferase-
based assay provided a high-resolution view of L1
kinetics, which can be summarized into three distinct
phases relative to the assay timeframe (Figure 5). The
ﬁrst phase shows inactivity (from 0 to 24h
post-transfection) as minimal L1 signal was detected
when cells were treated prior to 24 h post-transfection.
The second phase lasts 24h (from 24 to 48h
post-transfection) during which L1 activity increased
exponentially. In fact, reproducible and statistically sig-
niﬁcant signals could be detected from CAG-ORFeus at
24 h post-transfection. The third phase spans 48h (from
48 to 96 h post-transfection), when L1 retrotransposition
returned to a slower rate and eventually reached 100%
activity. These three distinct phases were observed for all
three L1 donor elements when treated with 3TC
(Figure 5B) as well as for 50-UTR-L1RP when treated
with d4T (Supplementary Figure S1B), suggesting that
the overall kinetics of retrotransposition is invariant
among L1 elements with different intrinsic activities. We
conﬁrmed the timing and kinetics of L1 retrotransposition
by performing time-course experiments (Figure 6). The
earliest time point when signiﬁcant Fluc signals can be
detected for CAG-ORFeus was 33h post-transfection;
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delay in detecting CAG-ORFeus activity reﬂects the time
that is needed for the reporter gene to be expressed from
L1 insertions (see Results section). Indeed, when de novo
L1 insertions were quantiﬁed directly by a sensitive qPCR
method, signiﬁcant signals can be detected as early as at
21h post-transfection (Figure 6D). Thus, the high sensi-
tivity and the broad dynamic range of our luciferase-based
assays afford us an intimate view of kinetics of retrotran-
sposition from plasmid-borne donor L1s.
The current study has generated a repertoire of L1
retrotransposition vectors that are equipped with dual-
luciferase reporters. These vectors feature two different
L1 donor elements, including a native human L1RP (22)
and a synthetic mouse L1 ORFeus (23,24), and a collection
of promoter elements for each donor element. ORFeus
vectors consistently display higher retrotransposition
frequencies than L1RP vectors as previously reported
(24) (45-fold higher when both donor elements were
regulated by the CAG promoter; Figure 4B). In fact,
CAG-ORFeus is the most active retrotransposition
vector in our dual-luciferase reporter assay: it yields an
NLR signal of >100 even at 2 days post-transfection
(Figure 6B), and is thus well suited for applications that
demand short assay timeframes. We also compared a
series of L1RP vectors that are regulated by single or
tandem combinations of different promoters including
the native human L1 promoter 50-UTR and heterologous
promoters CMV and CAG (Figure 3B). Overall retrotran-
sposition frequencies vary by 20-fold among these vectors
in the following order: CAG>CMV+CAG>CMV+
50-UTR>50-UTR>CMV. It should be noted here that
the promoter strength is not necessarily the only
determinant of the overall retrotransposition output. For
example, the 50-UTR of human L1.3 harbors cryptic splice
sites that may affect the processing of full-length L1 tran-
scripts (29). However, the potential contribution from
such alternative splicing events has not been evaluated in
our assay. In addition, previous studies using the
ﬁrst-generation neo-based assay suggest that the overall
effect of different promoters on retrotransposition is
context dependent. When the native human L1.2
element was tested, the exact order of
CMV+50-UTR>50-UTR>CMV was observed (16). In
contrast, the 50-UTR promoter from two other human
L1 elements, L1.3 and L1RP, yielded higher frequencies
of retrotransposition than the tandem CMV+50-UTR
promoter (22). Thus, to facilitate cross-study comparison
of retrotransposition results, we recommend the use of
singular promoters. As a general guideline, CAG is the
promoter of choice if the highest activity is desired,
CMV is an attractive alternative as it has a much
smaller size (0.6kb for CMV versus 1.7kb for CAG),
and ﬁnally the use of 50-UTR is required if the regulation
of native L1 promoter is the focus of the study.
In summary, the newly established luciferase-based
assays for L1 retrotransposition are rapid, sensitive and
highly efﬁcient. We have shown that high-throughput
testing of L1 retrotransposition can be performed in
24-well or 96-well plates. High signal-to-noise ratios
were obtained from 96-well plates even with standard
50-UTR-L1RP elements, suggesting it has the potential to
be further miniaturized into 384-well or higher density
formats. Since the initial demonstration of retrotran-
sposition by a cloned L1 in cultured cells, retrotran-
sposition assays have been playing a pivotal role in
unraveling mechanistic aspects of L1 movement. Aided
by its short assay timeframe, the luciferase-based assay
is expected to facilitate routine tests for L1 function as
well as large-scale screening efforts, such as genome-wide
screening of host factors or compounds, which modulate
L1 retrotransposition.
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Figure 7. Miniaturization of single-vector dual-luciferase L1 assays. L1
vectors with different coding sequences and promoters, including
pYX016 (CAG-ORFeus), pYX017 (CAG-L1RP), pYX014
(50-UTR-L1RP) and pYX015 (50-UTR-JM111), were evaluated in
24-well (Figure 4A) and 96-well plates, respectively. L1 activities are
expressed as NLRs relative to the background signal from pYX015,
and are graphed as a scatter plot. The x- and y-axes represent data
from 96- and 24-well plates, respectively. Error bars represent
mean±SE (N=10 for 96-well data; N=4 for 24-well data). A
power trendline is shown (y=1.060x
1.042; R
2=0.996).
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